Altered H3 histone acetylation impairs high-fidelity DNA repair to promote cerebellar degeneration in spinocerebellar ataxia type 7
Male
0301 basic medicine
cerebellum
DNA Repair
Medical Physiology
610
translocation
Neurodegenerative
Article
epigenetic dysregulation
Histones
Mice
03 medical and health sciences
Rare Diseases
spinocerebellar ataxia
Cerebellar Diseases
616
Genetics
2.1 Biological and endogenous factors
Animals
Humans
Spinocerebellar Ataxias
Eye Disease and Disorders of Vision
Ataxin-7
Neurons
Human Genome
Neurosciences
neurodegeneration
Acetylation
ataxin-7
Biological Sciences
Stem Cell Research
Brain Disorders
ChIP-seq
Biological sciences
repair
Neurological
DNA damage
Female
Biochemistry and Cell Biology
epigenetic dysregulation
Peptides
polyglutamine
DOI:
10.1016/j.celrep.2021.110062
Publication Date:
2021-11-30T22:12:14Z
AUTHORS (12)
ABSTRACT
A common mechanism in inherited ataxia is a vulnerability of DNA damage. Spinocerebellar ataxia type 7 (SCA7) is a CAG-polyglutamine-repeat disorder characterized by cerebellar and retinal degeneration. Polyglutamine-expanded ataxin-7 protein incorporates into STAGA co-activator complex and interferes with transcription by altering histone acetylation. We performed chromatic immunoprecipitation sequencing ChIP-seq on cerebellum from SCA7 mice and observed increased H3K9-promoter acetylation in DNA repair genes, resulting in increased expression. After detecting increased DNA damage in SCA7 cells, mouse primary cerebellar neurons, and patient stem-cell-derived neurons, we documented reduced homology-directed repair (HDR) and single-strand annealing (SSA). To evaluate repair at endogenous DNA in native chromosome context, we modified linear amplification-mediated high-throughput genome-wide translocation sequencing and found that DNA translocations are less frequent in SCA7 models, consistent with decreased HDR and SSA. Altered DNA repair function in SCA7 may predispose the subject to excessive DNA damage, leading to neuron demise and highlights DNA repair as a therapy target.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (55)
CITATIONS (14)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....